1Vang R, Cooley LD, Harrison WR, et al. Immunohistochemieal deterruination of HER-2/neu expression in invasive breast carcinoma[ J]. Am J Clin Pathol,2000 ,113 ( 5 ) :669 - 674. 被引量：1
2Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network [J]. Nat Rev Mol Cell Biol,2001,2(2) :127 - 137. 被引量：1
3Klapper LN, Waterman H, Sela M, et al. Tumor-inhibitory antibodies to HER-2/ErhB-2 may act by recruiting c-Cb1 and enhancing ubiquitination of HER-2 [ J ]. Cancer Res,2000,60 ( 13 ) : 3384 - 3388. 被引量：1
4McKay JA, Murray LJ, Curran S, et al. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases[ J]. Eur J Cancer,2002,38 ( 17 ) :2258 - 2264. 被引量：1
9Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists [ J ]. Chest, 2005,128 ( 6 ) :3975 - 3984. 被引量：1
10Di Carlo A, Mariano A, D'Alessandro V, et al. Evaluation of epidermal growth factor receptor, carcinoembryonie antigen and Lewis carbohydrate antigens in human colorectal and liver neoplasias[J]. Oncol Rep,2001,8(2) :387 -392. 被引量：1
2Vang R. Linda D. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma [J ]. Am J Clin Pathol, 2000, 113 : 669 - 674. 被引量：1
3Yamaguchi A,Urano T,Fushida S,et al. Inverse association of nm23-Hl expression by colorectal cancer with liver metastasis[J]. Br J Cancer,1993,68.1020. 被引量：1
4Selim A G A, Ayat G,Clive A. C-erbB-2 oncoprotein in apocfine adenosis of the breast[J]. J Pathol, 2000,191:138- 142. 被引量：1
5Gusterson B A, Gullick W J, Wenter D J, et al. Immunohistochemical localization of C-erbB-2 in human breast carcinomas[J]. Mol Cell Probes,1998,2(1):383. 被引量：1
6Tahara E. Genetic alterations in human gastrointestinal cancer:the application to molecular diagnosis[J]. Cancer, 1995, 75:1410. 被引量：1
7Ming S C. Gastric carcinoma,a pathohistological classification[J]. Cancer, 1977,39,2475. 被引量：1
8Greider C W. Telomerase activity ,cell proliferation and cancer[J]. Proc Natl Acad Sci USA,1998,95(1),90-92. 被引量：1
9Baretton G B, Diebold J, Christoforis G, et al. Apoptosis and immunohistochemical bel-2 expression in colorectal adenomas and carcinomas[J ]. Cancer, 1996,77,255- 264. 被引量：1
3Sakaguchi S. Naturally arising FoxP3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to serf and non-self[ J ]. Nat Immunol, 2005,6 (4) :345 -352. 被引量：1
4Williams LM, Rudensky AY. Maintenance of the FoxP3-dependent developmental program in mature regulatory T cells requires continued expression of FoxP3 [ J ]. Nat Immunol,2007,8 ( 3 ) :277-284. 被引量：1
5Fernando NH,Hurwitz HI.Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer[J].Semin Oncol,2003,30(3 Suppl 6):39-50. 被引量：1
6Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil,and leucovorin for metastatic colorectal cancer[J].N Engl J Med,2004,350(23):2335-2342. 被引量：1
7Hurwitz HI,Fehrenbacher L,Hainsworth JD,et al.Bevacizumab in combination with fluorouracil and leucovorin:an active regimen for first-line metastatic colorectal cancer[J].J Clin Oncol,2005,23(15):3502-3508. 被引量：1
8Stintzing S,Heinemann V,Moosmann N,et al.The treatment of colorectal carcinoma with monoclonal antibodies:the importance of KRAS mutation analysis and EGFR status[J].Dtsch Arztebl Int,2009,106(12):202-206. 被引量：1
9Lenz HJ,Van Cutsem E,Khambata-Ford S,et al.Multicenter phase Ⅱ and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan,oxaliplatin,and fluoropyrimidines[J].J Clin Oncol,2006,24(30):4914-4921. 被引量：1
10Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359(17):1757-1765. 被引量：1
